Abstract
Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have